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ABSTRACT
This study investigated the prevalence of the
erm(A), erm(B) and erm(C) genes among 122 MLS-
resistant clinical isolates of Staphylococcus aureus
from a Turkish university hospital. Of these
isolates, 44 were inducibly resistant and 78 were
constitutively resistant. The presence of one or
more erm genes was demonstrated in 114 isolates;
the erm(C) gene was detected in 97 isolates, and
the erm(A) gene was detected in 96 isolates.
Seventy-eight isolates harboured both erm(A)
and erm(C). The combination of erm(A), erm(B)
and erm(C) genes was detected in only one isolate.
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Macrolide (erythromycin), lincosamide (clinda-
mycin) and streptogramin B (vernamycin Ba)
antibiotics inhibit protein synthesis by binding
to overlapping sites in the 50S ribosomal sub-
unit [1]. Although they are chemically distinct
antibiotics, they have a similar mode of action.
Emergence of drug-resistant, especially methicil-
lin-resistant, Staphylococcus strains, has led to the
investigation of possible new antibiotics for the
treatment of staphylococcal infections. Use of
macrolide, lincosamide and streptogramin (MLS)
antibiotics is limited for staphylococcal infections,
but they are often considered as an alternative
treatment regiment [2,3].
Three different resistance mechanisms for
macrolide antibiotics have been described in sta-
phylococci, but the main mechanism involves
target-site modification following methylation of
the ribosome. The methylase enzyme adds one or
two methyl groups to the adenine residue in the 23S
rRNA moiety, and thereby decreases the affinity of
the ribosomal subunit for MLS antibiotics. Cross-
resistance to these chemically unrelated antibiotics
is observed since their binding sites overlap. The
second mechanism of resistance involves an efflux
system that results in resistance to macrolides and
streptogramin B antibiotics. The third mechanism
involves inactivation of antibiotics by the enzymes
acetyltransferase, hydrolase, nucleotidyltranferase
and phosphotransferase [4–6].
MLS resistance in staphylococci can be either
constitutively or inducibly expressed. While iso-
lates showing constitutive resistance are resistant
to 14-membered (erythromycin, roxithromycin,
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clarithromycin), 15-membered (azithromycin), 16-
membered (spiramycin, josamycin, miomycin and
midecamycin) macrolides and clindamycin, iso-
lates showing inducible resistance are resistant to
14- and 15-membered macrolides only [6,7].
Three main erm (erythromycin ribosome
methylation) genes, i.e., erm(A), erm(B) and
erm(C), have been described in staphylococci.
The erm(A) gene is located on transposon Tn554,
which has insertion sites in the Staphylococcus
aureus chromosome. Structural alterations in con-
stitutively or inducibly expressed erm(A) genes
have been demonstrated [6,8,9]. The erm(C) gene
has been found on a 3.7-kb element on a plasmid,
pE194, and has also been found on smaller
plasmids. The erm(B) gene is located on transpo-
son Tn551 [6]. Other genes, such as erm(F) and
erm(Y), may also be responsible for MLS resist-
ance [10,11].
The prevalence of erm genes in MLS-resistant
S. aureus isolates has been demonstrated previ-
ously [12–15]. As the prevalence of MLS resistance
and erm genes varies between countries and indi-
vidual hospitals, the present study investigated, for
the first time, the prevalence of the erm(A), erm(B)
and erm(C) genes in MLS-resistant clinical isolates
of S. aureus from a university hospital in Turkey.
Hacettepe University Hospital is a 1150-bed
hospital with 600 000 admissions annually.
Antibiotic use is strictly controlled by the infec-
tious diseases control committee of the hospital.
Data concerning the prevalence of MLS resistance
and resistance phenotypes in staphylococci in this
hospital have been reported previously [16]. In
this previous study, 500 consecutive clinical iso-
lates of staphylococci were collected from differ-
ent adult inpatients between June 1996 and June
1998. Of the 500 isolates, 132 (26.4%) were
resistant to MLS antibiotics, with 91 (18.2%) being
constitutively resistant, and 40 (8%) being induc-
ibly resistant. The MS phenotype (resistance to
macrolides and lincosamides only) was detected
in only one isolate. Of the 132 resistant isolates,
122 were S. aureus and ten were coagulase-
negative staphylococci.
In the present study, 122 MLS-resistant
S. aureus isolates, 104 of which were methicil-
lin-resistant and 18 were methicillin-susceptible,
were retested for MLS resistance by the disk-
diffusion method described by Jenssen et al.
[17]. The absence of inhibition zones around
the antibiotic disks was considered to be indic-
ative of constitutive resistance. Flattening or
blunting of the shape of the clindamycin and
vernamycin Ba inhibition zones, adjacent to the
erythromycin disk, was considered to be indic-
ative of inducible resistance [7,17]. Methicillin
resistance was determined by the broth macro-
dilution test [18].
Total DNA of all isolates was prepared by the
boiling method [19]. The primers described by
Lina et al. [13] were used for amplification of the
erm(A), erm(B) and erm(C) genes [13]. Amplifica-
tion products were visualised following electro-
phoresis on agarose 1.5% w ⁄ v gels. Table 1
summarises the distribution of the erm genes,
grouped according to the methicillin resistance of
the isolates. The ratio of constitutively MLS-
resistant isolates to inducibly-resistant isolates
(approximately 2 : 1) may reflect the more fre-
quent use of non-inducing MLS antibiotics in the
hospital studied.
Constitutively-resistant isolates have been
reported to be the predominant form of resist-
ance in some previous studies, whereas others
have found that the inducible resistance pattern
is more frequent [13,15,17]. In the present study,
78 isolates harboured both the erm(A) and
erm(C) genes. Similarly, in the study by Melter
et al. [12], 64 of 100 isolates contained both
erm(A) and erm(C), which was the predominant
pattern of resistance. All except one of the
methicillin-susceptible S. aureus (MSSA) isolates
in the present study were inducibly MLS-resist-
ant, and the erm(C) gene was the predominant
gene expressed. Lina et al. [13] also reported
Table 1. Distribution of erm genes
among macrolide-lincosamide-
streptogramin (MLS)-resistant iso-








Inducible MLS (n = 44)
MSSA (n = 17) 1 9 7 – –
MRSA (n = 27) 11 2 12 – 2
Constitutive MLS (n = 78)
MSSA (n = 1) – – 1 – –
MRSA (n = 77) 5 7 58 1 6
Total (n = 122) 17 18 78 1 8
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that the inducible phenotype was predominant
among MSSA, with 25% of isolates having
erm(C) as a single MLS resistance gene. In the
study by Spiliopoulou et al. [15], erm(C) was the
most frequent gene among constitutively MLS-
resistant methicillin-resistant S. aureus isolates.
As in previous studies of clinical isolates of
staphylococci, erm(B) was rare, being detected in
only one isolate in the present study. However,
erm(B) has been detected in isolates of Staphy-
lococcus intermedius, Staphylococcus xylosus and
Staphylococcus hyicus [20]. Future studies should
investigate the possible presence of other erm
genes and ribosomal mutations that have been
defined recently [4,10,11].
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